| Biological Products |
Indications |
Expected Expiry date |
| Adalimuzumab (Humara) |
Rhematoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease |
2018(EU)
2016(US) |
| Bevacizumab (Avastin) |
Metastatic colorectal cancer, HER2 negative breast cancer |
2022 (EU)
2019 (US) |
| Cetuximab( Erbitux) |
EGFR expressing metastatic colorectal cancer, squamous cell carcinoma of the head and neck |
2014(EU)
2016(US) |
| Etanercept (Enbrel) |
Rheumatoid arthritis,ankylosing spondylitis, plaque psoriasis |
2015(EU)
2013 (US) |
| Infliximab (Remicad) |
Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis |
2014(EU)
2018(US) |
| Palivizumab (Synagis) |
Respiratory disease caused by respiratory syncytial virus |
2015(EU)
2015(US) |
| Retuximab(Rituxan) |
CD-20-positive non-Hodgkinslymphoma,chronic lymphocytic leukemia, rheumatoid arthritis |
2013(EU)
2018(US) |
| Trastuzumab (Herceptin) |
HER2-positive breast cancer, metastatic breast cancer that overexpresses HER2 |
2014 (EU)
2019(US) |
|
